Bladder Cancer,Genitourinary Cancer Phase 2 BAYOU Trial: Investigating the Efficacy of Durvalumab and Olaparib in Platinum-Ineligible Bladder Cancer Apr 20, 2023
Bladder Cancer,Genitourinary Cancer Phase 2 RACE IT Study: Revolutionizing Treatment for Urothelial Carcinoma Patients Apr 20, 2023
Bladder Cancer,Genitourinary Cancer Neoadjuvant Pembrolizumab in MIBC: PURE-01 Follow Up Trial Apr 20, 2023
Bladder Cancer,Genitourinary Cancer Enfortumab Vedotin vs. Standard Chemotherapy for Advanced Urothelial Cancer: Phase 3 Results from EV-301 Apr 20, 2023
Genitourinary Cancer,RCC (Renal Cell Carcinoma) Comparing Perioperative Nivolumab vs Observation in RCC Patients Undergoing Nephrectomy: PROSPER Phase 3 Study Apr 17, 2023
Genitourinary Cancer,RCC (Renal Cell Carcinoma) Phase 2 LITESPARK-004: Belzutifan, a HIF-2α Inhibitor, for VHL Disease-Associated Neoplasms Apr 17, 2023
Genitourinary Cancer,RCC (Renal Cell Carcinoma) Telaglenastat Plus Cabozantinib vs. Placebo Plus Cabozantinib in Advanced RCC Patients:CANTATA Phase 2 Trial Apr 17, 2023
Genitourinary Cancer,RCC (Renal Cell Carcinoma) Phase III NKTR-214: BEMPEG Results: BEMPEG and NIVO vs. Sunitinib or Cabozantinib in RCC Apr 17, 2023
